Published in Urology on December 01, 2007
Sexual dysfunction after cystectomy and urinary diversion. Nat Rev Urol (2014) 0.81
Quality of life after radical cystectomy for bladder cancer in men with an ileal conduit or continent urinary diversion: A comparative study. Urol Ann (2013) 0.79
Health-related quality of life after cystectomy and urinary diversion for bladder cancer. Adv Urol (2011) 0.79
Prospective evaluation of health-related quality of life after radical cystectomy: focus on peri- and postoperative complications. World J Urol (2016) 0.76
Health Related Quality of life in bladder cancer. Current approach and future perspectives. Clujul Med (2017) 0.75
Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol (2009) 2.80
The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol (2007) 2.77
A molecular taxonomy for urothelial carcinoma. Clin Cancer Res (2012) 2.37
Urinary bladder cancer treated with radical cystectomy: perioperative parameters and early complications prospectively registered in a national population-based database. Scand J Urol (2014) 2.07
MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer (2009) 2.06
Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res (2010) 1.99
Guidelines on bladder cancer. Eur Urol (2002) 1.97
Increased concentrations of polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with testicular cancer. Environ Health Perspect (2003) 1.89
Polymorphisms in DNA repair and metabolic genes in bladder cancer. Carcinogenesis (2003) 1.78
Human bladder carcinoma is dominated by T-regulatory cells and Th1 inhibitory cytokines. J Urol (2007) 1.70
Gene expression signatures predict outcome in non-muscle-invasive bladder carcinoma: a multicenter validation study. Clin Cancer Res (2007) 1.68
Analysis of HER2 expression in primary urinary bladder carcinoma and corresponding metastases. BJU Int (2005) 1.58
Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57
Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One (2012) 1.56
Treatment delay and prognosis in invasive bladder cancer. J Urol (2005) 1.53
Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol (2005) 1.53
Pathologic downstaging is a surrogate marker for efficacy and increased survival following neoadjuvant chemotherapy and radical cystectomy for muscle-invasive urothelial bladder cancer. Eur Urol (2011) 1.51
Defecation disturbances after cystectomy for urinary bladder cancer. BJU Int (2010) 1.46
Hexyl aminolevulinate fluorescence cystoscopy: new diagnostic tool for photodiagnosis of superficial bladder cancer--a multicenter study. J Urol (2003) 1.33
Neoadjuvant cisplatinum based combination chemotherapy in patients with invasive bladder cancer: a combined analysis of two Nordic studies. Eur Urol (2004) 1.28
Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics (2008) 1.24
Hexaminolevulinate-guided fluorescence cystoscopy in the diagnosis and follow-up of patients with non-muscle-invasive bladder cancer: review of the evidence and recommendations. Eur Urol (2010) 1.24
Zinc-based fixative improves preservation of genomic DNA and proteins in histoprocessing of human tissues. Lab Invest (2003) 1.23
A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One (2011) 1.21
Detecting homozygous deletions in the CDKN2A(p16(INK4a))/ARF(p14(ARF)) gene in urinary bladder cancer using real-time quantitative PCR. Clin Cancer Res (2003) 1.16
Neoadjuvant cisplatin-methotrexate chemotherapy for invasive bladder cancer -- Nordic cystectomy trial 2. Scand J Urol Nephrol (2002) 1.14
Positron emission tomography with C11-acetate for tumor detection and localization in patients with prostate-specific antigen relapse after radical prostatectomy. Urology (2006) 1.14
Impact of thawing on RNA integrity and gene expression analysis in fresh frozen tissue. Diagn Mol Pathol (2009) 1.13
A second-look TUR in T1 transitional cell carcinoma: why? Eur Urol (2004) 1.13
Proteomic analysis of urinary biomarker candidates for nonmuscle invasive bladder cancer. Proteomics (2011) 1.09
DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics (2012) 1.07
Cathepsin E, maspin, Plk1, and survivin are promising prognostic protein markers for progression in non-muscle invasive bladder cancer. Am J Pathol (2012) 1.04
Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol (2013) 1.03
Multicenter validation of cyclin D1, MCM7, TRIM29, and UBE2C as prognostic protein markers in non-muscle-invasive bladder cancer. Am J Pathol (2012) 1.03
Lymph node metastasis in bladder cancer. Eur Urol (2005) 1.02
A population-based study of 538 patients with newly detected urinary bladder neoplasms followed during 5 years. Scand J Urol Nephrol (2003) 1.01
Distressful symptoms after radical radiotherapy for urinary bladder cancer. Radiother Oncol (2002) 1.00
Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer (2007) 1.00
Alternating mitomycin C and BCG instillations versus BCG alone in treatment of carcinoma in situ of the urinary bladder: a nordic study. Eur Urol (2003) 1.00
Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res (2007) 0.99
Population-based study of treatment guided by tumor marker decline in patients with metastatic nonseminomatous germ cell tumor: a report from the Swedish-Norwegian Testicular Cancer Group. J Clin Oncol (2011) 0.99
Focal amplifications are associated with high grade and recurrences in stage Ta bladder carcinoma. Int J Cancer (2010) 0.99
Decreased expression of RNA-binding motif protein 3 correlates with tumour progression and poor prognosis in urothelial bladder cancer. BMC Urol (2013) 0.96
Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol (2006) 0.94
Low-grade Ta (noninvasive) urothelial carcinoma of the bladder. Urology (2005) 0.92
Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol (2003) 0.92
Concentrations of polychlorinated biphenyls in blood and the risk for testicular cancer. Int J Androl (2004) 0.92
Analysis of clinical characteristics, management and survival of patients with Ta T1 bladder tumours in Sweden between 1997 and 2001. Scand J Urol Nephrol (2006) 0.90
Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol (2007) 0.90
Incontinent urinary diversion. BJU Int (2008) 0.90
Recurrent and multiple bladder tumors show conserved expression profiles. BMC Cancer (2008) 0.89
Hygiene and urinary tract infections after cystectomy in 452 Swedish survivors of bladder cancer. BJU Int (2009) 0.89
Labelling chemistry and characterization of [90Y/177Lu]-DOTA-ZHER2:342-3 Affibody molecule, a candidate agent for locoregional treatment of urinary bladder carcinoma. Int J Mol Med (2007) 0.88
HER-2, EGFR, COX-2 expression status correlated to microvessel density and survival in resected non-small cell lung cancer. Acta Oncol (2004) 0.87
[177Lu]pertuzumab: experimental therapy of HER-2-expressing xenografts. Cancer Res (2007) 0.87
Prediction of recurrence in Ta urothelial cell carcinoma by real-time quantitative PCR analysis: a microarray validation study. Int J Cancer (2006) 0.86
HER-2--a possible target for therapy of metastatic urinary bladder carcinoma. Acta Oncol (2002) 0.86
Pelvic exenteration for advanced and recurrent malignancy. World J Surg (2010) 0.86
Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol (2011) 0.86
Sleep disturbances decrease self-assessed quality of life in individuals who have undergone cystectomy. J Urol (2010) 0.85
Microbial flora in ileal and colonic neobladders. Eur Urol (2004) 0.84
Quality of life in patients with bladder cancer. Urol Oncol (2005) 0.84
Results of second-look resection after primary resection of T1 tumour of the urinary bladder. Scand J Urol Nephrol (2005) 0.84
Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Incidence, characteristics and preoperative detection. Scand J Urol Nephrol (2007) 0.83
Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol (2011) 0.83
Use of bacillus Calmette-Guérin in stage T1 bladder cancer: Long-term observation of a population-based cohort. Scand J Urol (2014) 0.83
A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol (2009) 0.82
Local recurrence and progression of non-muscle-invasive bladder cancer in Sweden: a population-based follow-up study. Scand J Urol (2015) 0.82
Radiobromination of anti-HER2/neu/ErbB-2 monoclonal antibody using the p-isothiocyanatobenzene derivative of the [76Br]undecahydro-bromo-7,8-dicarba-nido-undecaborate(1-) ion. Nucl Med Biol (2004) 0.82
High frequency of prostate antigen-directed T cells in cancer patients compared to healthy age-matched individuals. Prostate (2009) 0.82
Randomized phase II marker lesion study evaluating effect of scheduling on response to intravesical gemcitabine in recurrent Stage Ta urothelial cell carcinoma of the bladder. Urology (2005) 0.82
Reduced expression of ezrin in urothelial bladder cancer signifies more advanced tumours and an impaired survival: validatory study of two independent patient cohorts. BMC Urol (2014) 0.82
Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol. Scand J Urol (2012) 0.82
A novel strategy based on histological protein profiling in-silico for identifying potential biomarkers in urinary bladder cancer. BJU Int (2009) 0.81
Relative importance of sources of symptom-induced distress in urinary bladder cancer survivors. Eur Urol (2003) 0.80
Gene expression analysis for the prediction of recurrence in patients with primary Ta urothelial cell carcinoma. Eur Urol (2006) 0.80
Urothelial carcinoma in the prostatic urethra and prostate: current controversies. Expert Rev Anticancer Ther (2007) 0.80
Analysis of progression and survival after 10 years of a randomized prospective study comparing mitomycin-C and bacillus Calmette-Guérin in patients with high-risk bladder cancer. BJU Int (2007) 0.79
Tumour expression of bladder cancer-associated urinary proteins. BJU Int (2013) 0.79
Mucosal host responses to bacteriuria in colonic and ileal neobladders. Eur Urol (2006) 0.79
Radiobromination of humanized anti-HER2 monoclonal antibody trastuzumab using N-succinimidyl 5-bromo-3-pyridinecarboxylate, a potential label for immunoPET. Nucl Med Biol (2005) 0.79
Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol (2013) 0.79
Prognostic significance of homozygous deletions and multiple duplications at the CDKN2A (p16INK4a)/ARF (p14ARF) locus in urinary bladder cancer. Scand J Urol Nephrol (2006) 0.78
The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS). BJU Int (2011) 0.78
Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? World J Urol (2009) 0.78
Bladder neoplasms--regions at chromosome 9 with putative tumour suppressor genes. Scand J Urol Nephrol (2003) 0.78
Expression of UPA and UPAR is associated with the clinical course of urinary bladder neoplasms. Int J Cancer (2002) 0.78
Urinary diversion after cystectomy for bladder cancer: a population-based study in Sweden. Scand J Urol Nephrol (2010) 0.78
The prognostic role of the STK15 T91A polymorphism and of STK15 mRNA expression in patients with urothelial cell carcinoma. Anticancer Res (2007) 0.77
The rationale behind recommendations for follow-up after urinary diversion: an evidence-based approach. Scand J Urol Nephrol (2007) 0.77